We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest trading session, Novavax (NVAX - Free Report) closed at $6.85, marking a -2.28% move from the previous day. This move lagged the S&P 500's daily loss of 0.13%. On the other hand, the Dow registered a loss of 0.39%, and the technology-centric Nasdaq increased by 0.15%.
Shares of the vaccine maker have appreciated by 6.05% over the course of the past month, outperforming the Medical sector's loss of 0.96%, and the S&P 500's gain of 3.39%.
The upcoming earnings release of Novavax will be of great interest to investors. The company is expected to report EPS of -$0.19, down 119.19% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $118 million, indicating a 71.6% downward movement from the same quarter last year.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of $2.48 per share and revenue of $1.05 billion. These results would represent year-over-year changes of +301.63% and +53.6%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 6.34% downward. Novavax is currently sporting a Zacks Rank of #3 (Hold).
From a valuation perspective, Novavax is currently exchanging hands at a Forward P/E ratio of 2.83. This denotes a discount relative to the industry average Forward P/E of 19.79.
Meanwhile, NVAX's PEG ratio is currently 0.09. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.75 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Novavax (NVAX - Free Report) closed at $6.85, marking a -2.28% move from the previous day. This move lagged the S&P 500's daily loss of 0.13%. On the other hand, the Dow registered a loss of 0.39%, and the technology-centric Nasdaq increased by 0.15%.
Shares of the vaccine maker have appreciated by 6.05% over the course of the past month, outperforming the Medical sector's loss of 0.96%, and the S&P 500's gain of 3.39%.
The upcoming earnings release of Novavax will be of great interest to investors. The company is expected to report EPS of -$0.19, down 119.19% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $118 million, indicating a 71.6% downward movement from the same quarter last year.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of $2.48 per share and revenue of $1.05 billion. These results would represent year-over-year changes of +301.63% and +53.6%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 6.34% downward. Novavax is currently sporting a Zacks Rank of #3 (Hold).
From a valuation perspective, Novavax is currently exchanging hands at a Forward P/E ratio of 2.83. This denotes a discount relative to the industry average Forward P/E of 19.79.
Meanwhile, NVAX's PEG ratio is currently 0.09. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.75 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.